2026 Lambert-Eaton myasthenic syndrome strategy: epidemiology, VGCC biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Stiff person syndrome strategy: epidemiology, GAD65 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…

2026 Neuromyotonia strategy: epidemiology, CASPR2 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…

2026 Primary angiitis of the central nervous system strategy: epidemiology, IL-6 biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Adult-onset leukoencephalopathy with axonal spheroids strategy: epidemiology, CSF1R biology, clinical competition, recent deals, unmet need and market…

2026 Post-polio syndrome strategy: epidemiology, IGF-1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…

2026 Progressive muscular atrophy strategy: epidemiology, SOD1 biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Primary lateral sclerosis strategy: epidemiology, SOD1 biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Unverricht-Lundborg disease strategy: epidemiology, CSTB biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Spinal and bulbar muscular atrophy strategy: epidemiology, Androgen receptor biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Lafora disease strategy: epidemiology, GYS1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…

2026 Progressive myoclonic epilepsy strategy: epidemiology, GABA-A receptor biology, clinical competition, recent deals, unmet need and market attractiveness.